CN105213364B - The application of khellactone - Google Patents
The application of khellactone Download PDFInfo
- Publication number
- CN105213364B CN105213364B CN201510770874.XA CN201510770874A CN105213364B CN 105213364 B CN105213364 B CN 105213364B CN 201510770874 A CN201510770874 A CN 201510770874A CN 105213364 B CN105213364 B CN 105213364B
- Authority
- CN
- China
- Prior art keywords
- khellactone
- notopterygium root
- column
- apply according
- elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to technical field of traditional Chinese medicines, the present invention discloses application of the khellactone in injury of kidney cell is protected, so that clinically to prevent injury of kidney from providing a kind of more safely and effectively medications selections.Khellactone can effectively protect injury of kidney cell in safe dose, can be further developed as injury of kidney protection medicine, be with a wide range of applications.
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to the application of khellactone.
Background technology
Kidney is the vitals of human body, is that metabolism is normally carried out for ensureing the stabilization of organismic internal environment.
One of common acute disease of Urology Surgery, appropriate therapeutic scheme is made to injury of kidney during injury of kidney, the condition of the injury to mitigating patient, is changed
Kind prognosis situation is most important.Therefore, injury of kidney protects medicine in continuous research and development in recent years.
Research finds that Chinese medicine has significant protective effect to injury of kidney, and for Western medicine, Chinese medicine more heats
And safety, side effect are smaller.Notopterygium root, Umbelliferae, notopterygium root platymiscium are warm-natured, dissipate exterior cold；Wind-damp dispelling；Sharp joint；Analgesic.It is main outer
Feel chill；Have a headache lossless；Geomantic omen edema；Sore swollen toxin.For impotence and seminal emission, enuresis frequent micturition, waist and knee crymodynia, deficiency of the kidney and dyspnea, five
More diarrhea；External application curing vitiligo, alopecia areata.Relieving exterior syndrome and dispelling cold, expelling wind and eliminating dampness, analgesic.Contain various active material, such as Khellinum in notopterygium root
Lactone, RADIX PEUCEDANI aglycon, isopimpinellin, anisic acid para hydroxybenzene ethyl ester, byak-angelicin, bergaptol etc., these work
Property material has a variety of pharmacologic actions.Wherein, khellactone and being reported using its khellactone class cumarin as parent nucleus has
Significant expansion blood vessel and antivirus action.But at present and have no that document report khellactone has and prevent the work(of injury of kidney
Effect.
The content of the invention
In view of this, it is an object of the invention to provide the new opplication of khellactone, khellactone have prevent injury of kidney,
The effect of protecting injury of kidney cell, it can be applied in the preparation of injury of kidney protection medicine.
The chemical structural formula of khellactone is as follows：
Wherein, preferably, the khellactone includes cis khellactone and/or trans khellactone.
Preferably, the injury of kidney is renal damage caused by cis-platinum.
Khellactone acquiring way can both extract from the natural materials containing the composition such as notopterygium root, can also utilize and change
Learn synthetic method be subject to it is artificial synthesized, such as document《The improvement of cis khellactone synthetic method》(Juventus spring etc., contemporary Chinese should
With pharmacy, the 12nd phase of volume 27 in 2010), obtained preferably, khellactone of the present invention extracts from notopterygium root, more enter one
Step preferably, takes following methods to obtain：
Step 1, notopterygium root rhizome being crushed, add ethanol solution extraction, after extract solution filtering, concentration plus salt acid for adjusting pH is 2,
It is heated to reflux and concentrates to be evaporated acquisition crude extract；
Step 2, crude extract add ethanol solution and redissolved, and are adsorbed by macroporous resin column, successively 4 column volumes of water elution,
40% column volume of ethanol elution 3,60% column volume of ethanol elution 6,60% ethanol eluate is collected, remove solvent, concentration
To medicinal extract, ethyl acetate dissolving, filtering are then added, filtrate removes solvent, concentration, dried, and obtains notopterygium root extract；
After step 3, notopterygium root extract add methanol to dissolve, add in the thick silica gel of equivalent and stir, be poured into after drying
In 200-300 mesh silicagel columns containing 4~5 times of amounts；After petroleum ether balance D-101 pillars, petroleum ether-ethyl acetate 50 is utilized:
1、20:1、10:1 respectively elutes 4 column volumes, collects 10:1 elution position concentration is evaporated, and after adding methanol to dissolve, centrifugation, takes supernatant
Liquid, preparative separation is carried out using high pressure preparative liquid chromatography, obtains khellactone.
Wherein, the volume mass of notopterygium root rhizome and ethanol solution described in step 1 is than preferably 1g:6-10mL.
High pressure preparative liquid chromatography condition is preferably as follows：
The type preparative chromatograph of Agilent 1260, chromatographic column are Fuji C18 (250 × 50mm)；Mobile phase is acetonitrile-water；Inspection
Survey wavelength is 310nm；Elution program is 0~60min, acetonitrile 30%, water 70%；Flow velocity is 30mLmin-1；Column temperature is 30 DEG C.
It is preferably that crude extract adds 1 times of amount of notopterygium root rhizome gross weight that crude extract described in step 2, which adds ethanol solution and redissolved,
40% ethanol solution dissolves.
It is preferably D-101 type macroporous resin columns to state macroporous resin column.
The macroporous resin column weight is preferably 2 times of notopterygium root rhizome gross weight.
The concentration expressed in percentage by volume of ethanol solution described in step 1 is preferably 70%.
In the experiment of HK-2 cells renal injury model caused by cis-platinum of cis khellactone and trans khellactone
Show the protective effect to the security of normal HK-2 cells and to injury of kidney cell.Therefore, the present invention is provided in Khellinum
Application of the ester in injury of kidney protection medicine is prepared.
From above technical scheme, the invention provides application of the khellactone in injury of kidney cell is protected, so as to
Clinically to prevent injury of kidney from providing a kind of more safely and effectively medication selections.Khellactone can be effectively in safe dose
Injury of kidney cell is protected, injury of kidney protection medicine can be further developed as, be with a wide range of applications.
Brief description of the drawings
Fig. 1 show notopterygium root extract high pressure preparative liquid chromatography figure.
Embodiment
The invention discloses the application of khellactone, those skilled in the art can use for reference present disclosure, be suitably modified work
Skill parameter is realized.In particular, all similar replacements and change are aobvious and easy for a person skilled in the art
See, they are considered as being included in the present invention.Product of the present invention and preparation method and application are by preferably real
Example is applied to be described, related personnel substantially can not depart from present invention, in spirit and scope to method described herein
It is modified or suitably changes with combining with application, realizes and using the technology of the present invention.
The application with regard to khellactone provided by the present invention is described further below.
Embodiment 1：The extraction separation of khellactone
Notopterygium root rhizome is ground into coarse powder, 6~10 times of 70% ethanol solution is added by volume/mass and is extracted twice, often
Secondary 1.5 hours, merge filtered fluid, be concentrated into 1 times that medicinal material weight is added water to after no alcohol taste；Concentrate adds concentrated hydrochloric acid regulation pH
To 2,0.5 hour is heated to reflux, concentration is evaporated, and is added 40% ethanol solution of 1 times of amount of medicinal material weight and is completely dissolved it.Water
Solve D-101 macroporous resin column (blade diameter length ratio 1 of the liquid by 2 times of medicinal material weight:8) after adsorbing, 4 column volumes of water elution, 40%
3 column volumes of ethanol elution, 60% column volume of ethanol elution 6.60% ethanol eluate merges, and recycling design, is concentrated into leaching
Cream.Medicinal extract adds ethyl acetate solution, makes its dissolving complete, filtration, recycling design, is concentrated into medicinal extract, 60 DEG C of vacuum drying, powder
It is broken to produce notopterygium root extract.
After notopterygium root extract adds proper amount of methanol to dissolve, add in the thick silica gel (80-100 mesh) of equivalent and stir, dry
It is poured into afterwards in silica gel (200-300 mesh) post containing 4~5 times of amounts.After petroleum ether balance D-101 pillars, petroleum ether-second is utilized
Acetoacetic ester 50:1、20:1、10:1 respectively elutes 4 column volumes, collects 10:The concentration of 1 position is evaporated.Petroleum ether-ethyl acetate 10:1
After elution position adds methanol to dissolve, centrifugation, supernatant is taken, preparing liquid phase using high pressure is prepared, and collects khellactone chromatogram
Peak, khellactone is obtained after concentrate drying.
High pressure preparative liquid chromatography condition：The type preparative chromatograph of Agilent 1260, chromatographic column be Fuji C18 (250 ×
50mm)；Mobile phase is acetonitrile (A)-water (B)；Detection wavelength is 310nm；Elution program is 0~60min, A30%, B70%；Stream
Speed is 30mLmin-1；Column temperature is 30 DEG C.
Khellactone qualification result is as follows：
(-)-trans khellactone:1H NMR(400MHz,CD3OD)δ:6.25 (1H, d, J=9.5Hz, H-3), 7.88
(1H, d, J=9.5Hz, H-4), 7.46 (1H, d, J=8.6Hz, H-5), 6.80 (1H, d, J=8.6Hz, H-6), 3.74 (1H,
D, J=4.3Hz, H-3 '), 4.92 (1H d, J=4.3Hz, H-4 '), 1.38 (3H, s ,-CH3),1.45(3H,s,-CH3)。13C
NMR(100MHz,CD3OD)δ:163.5(C-2),112.7(C-3),146.4(C-4),129.9(C-5),113.8(C-6),
156.0(C-7),115.9(C-8),158.0(C-9),112.2(C-10),79.9(C-2′),66.1(C-3′),75.0(C-
4′),23.2(C-5′),25.0(C-6′)。
(+)-cis khellactone:1H NMR(400MHz,CD3OD)δ:6.24 (1H, d, J=9.5Hz, H-3), 7.86
(1H, d, J=9.5Hz, H-4), 7.44 (1H, d, J=8.6Hz, H-5), 6.76 (1H, d, J=8.6Hz, H-6), 3.75 (1H,
D, J=4.7Hz, H-3 '), 5.07 (1H d, J=4.7Hz, H-4 '), 1.42 (3H, s ,-CH3),1.43(3H,s,-CH3)。13C
NMR(100MHz,CD3OD)δ:163.4(C-2),112.8(C-3),146.3(C-4),129.9(C-5),113.7(C-6),
155.8(C-7),115.8(C-8),157.9(C-9),112.7(C-10),80.2(C-2′),62.1(C-3′),73.1(C-
4′),21.4(C-5′),26.9(C-6′)。
Embodiment 2：Khellactone causes the protective effect of HK-2 cell renal injury models to cis-platinum
1. materials and methods
1.1 cell people renal cells HK-2, purchased from China typical culture collection center.
1.2 main agents and instrument
Cis-platinum is purchased from sigma companies；Required basic culture solution (Dulbecco ' the s minimum essential of Dulbecco
Medium, DMEM)/F12 nutrient solutions, hyclone (fetal bovine serum, FBS), trypsase is purchased from U.S. Gibco
Company；MTT is purchased from green skies company.
The culture of 1.3HK-2 cells
HK-2 cells carry out cellar culture, 5%CO in the DMEM/F12 nutrient solutions containing 10%FBS2, 37 DEG C of cultures are to melting
The cell of conjunction phase is digested with 0.25% pancreatin, and passage, the cell for growth of taking the logarithm is tested.
Influence of 1.4 khellactones to HK-2 cell growths：
Take the logarithm growth period HK-2 cell, with 1 × 104Cells/100 μ l/ holes are inoculated in 96 well culture plates, treat cell
More than 80% is grown to, being changed to serum free medium culture 12h makes to be in synchronous regime, is separately added into 6.25,12.5,25,50,
The various concentration khellactones of 100,150 μ g/ml are cultivated under normal condition, control group：Cultivated in normal incubation medium, after 24h
It is placed under inverted microscope and observes cellular morphology change, the μ l of MTT solution 10 is added per hole, continue to be incubated in cell culture incubator
Supernatant is abandoned in 4h, suction, adds 150 μ lDMSO dissolving first a ceremonial jade-ladle, used in libations, using ELIASA using 570nm as Detection wavelength, 630nm is reference ripple
It is long, absorbance is read, every group sets 6 multiple holes, and each group is averaged, and experiment is repeated 3 times, and experimental result is shown in Table 1.
Influence OD value x ± s of the khellactone of table 1 to normal HK-2 cell growths
| Drug concentration (μ g/mL) | Trans khellactone (n=6) | Cis khellactone (n=6) |
| control | 0.65±0.01 | 0.64±0.04 |
| 6.25 | 0.65±0.04 | 0.63±0.04 |
| 12.5 | 0.65±0.02 | 0.64±0.02 |
| 25 | 0.66±0.01 | 0.64±0.01 |
| 50 | 0.67±0.02 | 0.66±0.02 |
| 100 | 0.64±0.03 | 0.67±0.03 |
| 150 | 0.60±0.01 | 0.63±0.01 |
The * compared with normal group：P ＜ 0.05
As seen from the results in Table 1, growth of the khellactone on normal HK-2 cells does not influence significantly compared with control group,
It is safe.
1.5 protective effect of drug
Take the logarithm growth period HK-2 cell, with 1 × 104Cells/100 μ l/ holes are inoculated in 96 well culture plates, treat cell
More than 80% is grown to, being changed to serum free medium culture 12h makes to be in synchronous regime, adds 80 μm of olL-1DDP of people respectively,
The various concentration khellactone normal condition cultures of 0,6.25,12.5,25,50,100,150 μ g/ml are separately added into simultaneously, are compareed
Group：Cultivated in normal incubation medium, be placed in after 24h under inverted microscope and observe cellular morphology change, MTT solution 10 is added per hole
μ l, continue to be incubated 4h in cell culture incubator, supernatant is abandoned in suction, adds the DMSO of 150 μ l 1 dissolving first a ceremonial jade-ladle, used in libations, using ELIASA with
570nm is Detection wavelength, and 630nm is reference wavelength, reads absorbance, and every group sets 6 multiple holes, and each group is averaged, experiment
It is repeated 3 times, experimental result is shown in Table 2.
Protective effect of the khellactone of table 2 to injury of kidney cell
| Drug concentration (μ g/mL) | Trans khellactone (n=6) | Cis khellactone (n=6) |
| control | 0.68±0.04 | 0.67±0.03 |
| Model | 0.50±0.02## | 0.50±0.05## |
| 6.25 | 0.50±0.03 | 0.49±0.06 |
| 12.5 | 0.51±0.02 | 0.51±0.05 |
| 25 | 0.51±0.03 | 0.51±0.04 |
| 50 | 0.58±0.02** | 0.56±0.03* |
| 100 | 0.56±0.03* | 0.55±0.01** |
| 150 | 0.50±0.01 | 0.50±0.04 |
The ## compared with normal group：P ＜ 0.01；The * compared with model group：p<0.05；**：P ＜ 0.01
As seen from the results in Table 2, model group has significant difference compared to control group, shows that cis-platinum causes HK-2 cell injury of kidney moulds
Type successfully constructs.And when khellactone drug concentration is 50,100 μ g/ml, there is significant protection to make to injury of kidney cell for it
With, show khellactone can be applied to injury of kidney protection medicine preparation in.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (9)
- The application of 1.50 μ g/ml khellactones or 100 μ g/ml khellactones in renal damage caused by cis-platinum protection medicine is prepared.
- 2. apply according to claim 1, it is characterised in that the khellactone includes cis khellactone and/or trans Khellactone.
- 3. apply according to claim 1, it is characterised in that the khellactone is extracted from notopterygium root and obtained.
- 4. apply according to claim 3, it is characterised in that the khellactone extracts separation by following methods and obtained：Step 1, notopterygium root rhizome is crushed, add ethanol solution extraction, after extract solution filtering, concentration plus salt acid for adjusting pH is 2, heating Flow back and concentrate and be evaporated acquisition crude extract；Step 2, crude extract add ethanol solution and redissolved, and are adsorbed by macroporous resin column, successively 4 column volumes of water elution, 40% 3 column volumes of ethanol elution, 60% column volume of ethanol elution 6,60% ethanol eluate is collected, remove solvent, be concentrated into leaching Cream, ethyl acetate dissolving, filtering are then added, filtrate removes solvent, concentration, dried, and obtains notopterygium root extract；After step 3, notopterygium root extract add methanol to dissolve, add in the thick silica gel of equivalent and stir, be poured into after drying containing 4~ In the 200-300 mesh silicagel columns of 5 times of amounts；After petroleum ether balance D-101 pillars, petroleum ether-ethyl acetate 50 is utilized:1、20: 1、10:1 respectively elutes 4 column volumes, collects 10:1 elution position concentration is evaporated, and after adding methanol to dissolve, centrifugation, takes supernatant, profit Preparative separation is carried out with high pressure preparative liquid chromatography, obtains khellactone.
- 5. apply according to claim 4, it is characterised in that the volume mass of notopterygium root rhizome and ethanol solution described in step 1 Than for 1g:6-10mL.
- 6. apply according to claim 4, it is characterised in that the high pressure preparative liquid chromatography condition is as follows：The type preparative chromatograph of Agilent 1260, chromatographic column are FujiC18 (250 × 50mm)；Mobile phase is acetonitrile-water；Detect ripple A length of 310nm；Elution program is 0~60min, acetonitrile 30%, water 70%；Flow velocity is 30mLmin-1；Column temperature is 30 DEG C.
- 7. apply according to claim 4, it is characterised in that crude extract described in step 2 adds ethanol solution and redissolved slightly to carry Thing adds the 40% ethanol solution dissolving of 1 times of amount of notopterygium root rhizome gross weight.
- 8. apply according to claim 4, it is characterised in that the macroporous resin column is D-101 type macroporous resin columns.
- 9. apply according to claim 4, it is characterised in that the macroporous resin column weight is 2 times of notopterygium root rhizome gross weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510770874.XA CN105213364B (en) | 2015-11-12 | 2015-11-12 | The application of khellactone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510770874.XA CN105213364B (en) | 2015-11-12 | 2015-11-12 | The application of khellactone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105213364A CN105213364A (en) | 2016-01-06 |
| CN105213364B true CN105213364B (en) | 2018-03-23 |
Family
ID=54982884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510770874.XA Active CN105213364B (en) | 2015-11-12 | 2015-11-12 | The application of khellactone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105213364B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107018983A (en) * | 2017-05-26 | 2017-08-08 | 江苏省中国科学院植物研究所 | A kind of natural angle-pyrancoumarins compound as agricultural bacteriocide purposes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1422159A (en) * | 2000-04-10 | 2003-06-04 | 宝生物工程株式会社 | Remedies |
-
2015
- 2015-11-12 CN CN201510770874.XA patent/CN105213364B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1422159A (en) * | 2000-04-10 | 2003-06-04 | 宝生物工程株式会社 | Remedies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105213364A (en) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN104620986B (en) | The induction of Radix Notoginseng adventitious root and method for tissue culture | |
| CN102138966A (en) | Tibetan capillaris extract and preparation method, pharmaceutical composition and use thereof | |
| CN103819445A (en) | Method for preparing two neo-pentenyl flavonoid compounds with hypolipidemic activity in fructus podophylli | |
| CN105287474B (en) | The application of anisic acid para hydroxybenzene ethyl ester | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN105213364B (en) | The application of khellactone | |
| CN105193885B (en) | A kind of notopterygium root extract and its preparation method and application | |
| CN101028322B (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN104873560A (en) | Plant general flavone and preparation method and application thereof | |
| CN102258094B (en) | Tea drink containing natural plants or natural plant extracts, and preparation method and application thereof | |
| CN105412083B (en) | The application of isopimpinellin | |
| CN105343052B (en) | The application of RADIX PEUCEDANI aglycon | |
| CN103804334B (en) | C is extracted from saussurea intybus15H18O5Method and application thereof | |
| CN105198943B (en) | A kind of entitled tea hill how glycosides A acylated flavonoids glucosides and its preparation method and application | |
| CN107753531B (en) | Wenwang-herba violae extract and application thereof in preparing anti-cancer drugs | |
| CN105193787B (en) | The application of byak-angelicin | |
| CN104782657A (en) | Plant destructive distillation liquid, its preparation and its application in improvement of content of effective components in hairy root of Salvia miltiorrhiza | |
| CN104857040A (en) | New purpose of embelia parviflora wall for preparing medicines for treating liver fibrosis | |
| CN110776409B (en) | Method for extracting pterocarpus indicus and application of extract in antitumor drugs | |
| CN107028965A (en) | Application and product of the yuenkanin or derivatives thereof in fat-reducing medicament is prepared | |
| CN101804128B (en) | Medicine composition, and use thereof in preparing medicine for curing inflammatory enteropathy | |
| CN104324021A (en) | GrcVillic acid and applications of GrcVillic acid, hydroquinone and Heliciopsis lobata active ingredients in preparation of anti-tumor and anti-inflammation drugs | |
| CN103405508A (en) | Method for extracting oestrogen active ingredients in cistanche | |
| CN100486600C (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating liver fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |